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Abstract
Introduction: Survival after a resected pancreatic ductal adenocarcinoma (PDAC) appears to be
improving. Yet, in spite of advancements, prognosis remains disappointing. This study analyses a
contemporary experience and identifies features associated with survival.
Methods: Kaplan–Meier analysis was conducted for 424 PDAC resections performed at two institutions
(2001–2011). Multivariate analysis was performed to elicit characteristics independently associated with
survival.
Results: The median, 1-, and 5-year survivals were 21.3 m, 76%, and 23%, with 30/90-day mortalities
of 0.7%/1.7%. 76% of patients received adjuvant therapy. Patients with major complications (Clavien
Grade IIIb-IV) survived equivalently to patients with no complications (P = 0.33). The median and 5-year
survival for a total pancreatectomy was 32.2 m/49%; for 90 ‘favourable biology’ patients (R0/N0/M0) was
37.3 m/40%; and for IPMN (9% of series) was 21.2 m/46%. Elderly (>75 yo) and nonelderly patients had
similar survival. Favorable prognostic features by multivariate analysis include lower POSSUM physiology
score, R0 resection, absence of operative transfusion, G1/G2 grade, absence of lymphovascular invasion,
T1/T2 stage, smaller tumor size, LN ratio <0.3, and receipt of adjuvant therapy.
Conclusion: This experience with resected PDAC shows decreasing morbidity and mortality rates along
with modestly improving long-term survival, particularly for certain subgroups of patients. Survival is
related to pathological features, pre-operative physiology, operative results and adjuvant therapy.
Received 1 July 2012; accepted 15 August 2012
Correspondence
Charles M. Vollmer Jr, Department of Surgery, University of Pennsylvania Perelman School of Medicine,
Philadelphia, PA 19104, USA. Tel: +1 215 349 8516. Fax: +1 215 349 8195. E-mail: charles.vollmer@
uphs.upenn.edu
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is among the most
aggressive malignancies and is one of the most frustrating diseases
to manage. With an annual death rate approaching incidence,
PDAC confers a dismal prognosis. While resection provides the
possibility of a long-term cure, ambiguous presentations often
mean that the disease is not diagnosed until it has reached an
advanced stage no longer amenable to surgery. For the ~15% of
pancreatic cancer patients who undergo resection,1 the required
procedures are among the most challenging in the realm of
abdominal surgery, with substantial post-operative morbidity and
mortality. In the 1960s and 70s, mortality rates as high as 25% led
some authors to suggest that pancreatic resections for PDAC
should be abandoned because of an unacceptable operative risk.2,3
Furthermore, initial reports of 1-year survival after resection were
dismal (around 50%),2 largely indicative of the severity of the
operative endeavour and perhaps less refined patient selection. As
recently as 1985, a study of national cancer data in the United
States reported a 9.4% operative mortality rate for pancreati-
coduodenectomy, and showed an actual 5-year survival of 3% for
cancer patients treated with this surgery.4
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The context for surgical resection of pancreatic cancer,
however, has changed dramatically in the past three decades.
Studies from the 1990s demonstrated dramatically lower mortal-
ity rates in high-volume centres, and pancreatic resections are now
increasingly performed by specialists with reported mortality
rates well under 5.0%.5–9 As operative performance has continued
to improve, surgeons have gradually expanded the indications for
surgery. Advanced age and venous invasion (portal vein and supe-
rior mesenteric vein) are no longer considered surgical contrain-
dications, and some groups have even suggested a role for arterial
resections and total pancreatectomies in selected situations.10 In
addition, recent data have suggested that at specialty practices
with significant hospital volume, lower post-operative complica-
tion rates can be achieved in spite of rising patient acuity.11,12
Specialty training in pancreatic surgery has also expanded in
scope and content significantly over the last 15 years and, although
hard to measure, has undoubtedly contributed to incremental
improvements in peri-operative outcomes.13,14
Post-operatively, patients are now treated with a broader array
of chemotherapeutic agents, and gemcitabine therapy has
replaced 5-fluorouracil as the standard of care in the United States
since its introduction in 1996. Patients have new options for the
delivery of radiation therapy, as a result of technological advances
in radiation oncology, such as intensity modulated radiation
therapy, Cyberknife and proton-beam technology. Furthermore,
the use of post-operative adjuvant therapy in the United States has
increased over the last two decades.15 Yet, in spite of modest
progress in these ancillary oncological modalities, surgical inter-
vention, the primary contributor to potential cure, is largely
underutilized for pancreatic cancer in the United States.16 This
may reflect outdated beliefs regarding post-operative morbidity
and mortality rates from the physician referral base.17
Furthermore, the reporting standards for surgical outcomes
have changed in recent years to address ambiguities in surgical
terminology. The Toronto group has developed and subsequently
refined an increasingly popular complication grading scale based
on clinical impact.18–20 Pancreatic fistulae and delayed gastric
emptying have been codified and graded through international
study group consensus to provide further consistency in the
literature.21,22 Pathological analysis is becoming increasingly
sophisticated, with features such as lymphovascular invasion,
perineural invasion and lymph node ratios commonly being
reported and correlated with patient outcomes.23 Verbeke et al.
have proposed a new approach for processing specimens and
ascribing resection margins, and further reports have demon-
strated its relevance in survival studies.24–26 Finally, the potential
utility of peri-operative risk assessment scores and nomograms
are suddenly coming into focus.27–30
In light of the advances attained by these multidisciplinary
contributions, and in the context of modern reporting standards,
this report aims to provide a contemporary analysis of a combined
experience with resected pancreatic adenocarcinoma at two high-
volume specialty centres. This study seeks to identify factors that
currently drive long-term survival as well as to scrutinize certain
scenarios now regularly faced in managing this disease.
Methods
This study was approved by the Institutional Review Boards at
both the Hospital of the University of Pennsylvania (HUP) and
the Beth Israel Deaconess Medical Center (BIDMC). A retrospec-
tive review of two prospectively maintained databases identified
424 resections for confirmed PDAC performed between 2001 and
2011 by five surgeons who specialize in pancreatic surgery. Resec-
tions included only pancreaticoduodenectomies, distal pancreate-
ctomies and total pancreatectomies. Patients with duodenal,
ampullary, bile duct and other periampullary neoplasms were
excluded from the study.
Variables accrued and analysed include patient characteristics,
comorbidities, pre-operative labs, tumour features, operative
details, post-operative management and complications, and post-
operative therapy. Pre-operative weight loss was defined as a
decrease in body weight of 10% or more. Median operating time
was defined as the time from incision to skin closure. Operative
transfusions were defined as transfusions received intra-
operatively or within the first 24 h thereafter. Duration of stay for
the index admission was computed from the operation date to the
discharge date. Total duration of stay reflects the additive time of
the index admission and any readmission time within 30 days of
discharge. The post-operative course of each patient at both insti-
tutions was reviewed by a single pancreatic surgeon (C.M.V.) and
scored according to the Clavien complication scale, the Inter-
national Study Group on Pancreatic Fistula (ISGPF) Pancreatic
Fistula Classification Scheme and the ISGPSDelayedGastric Emp-
tying Classification Scheme.19,21,22 Charlson, The Physiological
andOperative Severity Score for the enUmeration ofMortality and
Morbidity (POSSUM) and the Surgical Outcomes Analysis and
Research (SOAR) risk prediction scores were calculated for each
patient.27,28,30,31 Tumour specimens were analysed by an attending
pathologist and staged according to the American Joint Commit-
tee on Cancer (AJCC) 7th edn but did not regularly follow the
technique recently proposed by Verbeke et al.24 Resection margins
were defined as follows: R0, final margins devoid of a tumour; R1,
microscopic tumour present at the margin(s); and R2, gross
residual tumour present at the margin(s). The lymph node ratio
(LNR) was defined as the ratio of positive nodes to nodes exam-
ined. Pre-operative CA 19-9 values were inconsistently accrued
(20%of patients); therefore, theywere not included in the analysis.
Operatively placed drains were routinely removed on post-
operative day (POD) 5–7 (upon tolerance of a soft mechanical
diet) if fluid output remained low and amylase remained below
1000 IU/l. The standard oncological approach at both institu-
tions was to provide post-operative chemoradiation therapy, pre-
dominantly gemcitabine based. Standard radiation treatment
consisted of 50 Gy with chemosensitization by continuous infu-
sion with 5-fluorouracil (5-FU). Neoadjuvant therapy was infre-
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quently employed (<3%), in each case in the setting of initially
locally-unresectable tumours. Survival was identified through
hospital charts, contact with primary physicians and oncologists,
and confirmed by the Social Security Death Index. Disease-
specific survival was not accrued.
Statistical analyses were conducted using IBM SPSS, version 20
(SPSS Inc., Chicago, IL, USA). Summary statistics have been pro-
vided. The primary outcomemeasure was overall survival, defined
as the time from surgery to death or last known follow-up. Uni-
variate survival differences between dichotomized variables were
tested using the log-rank test, and the survival impact of continu-
ous variables was analysed using Cox’s regression. Survival curves
were generated according to the Kaplan–Meier method.32 To
assess factors independently associated with survival, a Cox pro-
portional hazard model was constructed from all univariate
factors with significance P < 0.1, utilizing forward conditional
modelling. In all, 107 variables (53 pre-operative, 18 peri-
operative, 24 post-operative and 12 pathological) were individu-
ally tested, and 23 were used to construct the multivariate model.
Comparisons between groups were assessed by Fisher’s exact test,
Pearson’s chi-squared test, or the Mann–Whitney U-test as indi-
cated. Independently associated differences were assessed by logis-
tic regression. All tests were two-sided and were considered
significant at P < 0.05.
Results
Patient characteristics
Four hundred and twenty-four patients were equally distributed
between two institutions (HUP, n = 202; BIDMC, n = 222). In
total, 341 (80.4%) pancreaticoduodenectomies, 61 (14.4%) distal
pancreatectomies and 22 (5.2%) total pancreatectomies were per-
formed. Pre-operative characteristics and comorbidities for these
patients are presented in Table 1.
Tumour features
Pathological features are presented in Table 2. Metastatic tumours
were all discovered intra-operatively – usually representing a
limited burden of metastatic disease with favourable resection
scenarios. Among just the node-positive patients the median LNR
was 0.19 [interquartile range (IQR): 0.10–0.32].
Perioperative features
Negative resection margins (R0) were achieved in 276 (65.1%) of
all patients. There were no R2 resections performed. The median
operating time was 5.9 h (IQR: 4.4–7.3). While the median esti-
mated blood loss (EBL) was 400 ml (IQR: 300–700), excessive
blood loss ( 1000 ml) occurred in 60 (14.2%) operations. This
was balanced by 73 operations (17.2%) where the EBL was <
250 ml. The overall operative transfusion rate was 27.4%. The
overall in-hospital transfusion rate was 39.4%. Resection of the
portal vein or SMV to achieve negative margins occurred in 21
patients (5.0%), of which 14 actually demonstrated venous
tumour invasion. Although almost all patients (n = 400) were
drained intra-operatively, percutaneous drains were required
postoperatively for 13 patients (3.1%), whereas reoperations,
usually for bleeding complications, were required for 17 patients
(4.0%). Parenteral nutrition was used to manage 68 patients
(16%) post-operatively. ICU transfers in the recovery period were
required 5.9% of the time. The median duration of stay after
surgery was 8 days (IQR: 7–11), and 72 (17%) patients were
Table 1 Patient characteristics and comorbidities
n (%)
Characteristics
Gender
Male 214 (50.5%)
Female 210 (49.5%)
Age (median/IQR) 67 (60–74)
Elderly (75) 101 (23.8%)
BMI (median/IQR) 25.7 (23.0–29.5)
Obese (BMI > 30) 86 (20.3%)
ASA Score
ASA I 8 (1.9%)
ASA II 147 (34.7%)
ASA III 262 (61.8%)
ASA IV 7 (1.7%)
Charlson score with age (median/IQR) 5 (4–6)
POSSUM physiological score (median/IQR) 18 (15–23)
SOAR score (median/IQR) 11 (9–12)
Pre-operative weight loss ( 10%) 133 (31.4%)
Pre-operative jaundice 281 (66.3%)
Pre-operative biliary stenting 145 (34.2%)
Comorbidities
HTN 233 (55.0%)
Diabetes 127 (30.0%)
GERD 118 (27.8%)
CAD 72 (17.0%)
Connective tissue disease 46 (10.8%)
Myocardial infarction 34 (8.0%)
COPD 33 (7.8%)
Asthma 26 (6.1%)
Peripheral vascular sisease 17 (4.0%)
Renal disease 17 (4.0%)
Cerebrovascular disease 16 (3.8%)
Congestive heart aailure 11 (2.6%)
Ulcer disease 9 (2.1%)
Liver disease 8 (1.9%)
Dementia 2 (0.5%)
IQR, interquartile range; BMI, body mass index, ASA, American Society
of Anesthesiologists; HTN, hypertension; GERD, gastroesophageal reflux
disease; CAD, coronary artery disease; COPD, chronic obstructive pul-
monary disease.
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readmitted within 1 month of the index operation. Readmitted
patients had a median total duration of stay (index and readmis-
sion) of 15 days (IQR: 11–19). Only 22 patients (5.2%) were
hospitalized for longer than 3 weeks. Post-operative complications
are presented in Table 3.
Application of adjuvant therapy
Information on oncological treatment was accrued on all but 24
patients (5.7%). Eleven patients (2.6%) received pre-operative
downstaging chemoradiation for initially unresectable tumors.
Otherwise, 324 patients (76.4%) received adjuvant chemotherapy
or chemoradiation therapy (CRT) with curative intent after the
operation. A small portion of patients (2.8%) received palliative
chemotherapy for metastatic disease discovered operatively or
before the intended initiation of formal adjuvant therapy.Another
53 patients (12.5%) did not receive adjuvant therapy by choice,
the discretion of their oncologist or owing to an unfavourable
post-operative course (complications/death) which precluded
further treatment. Among the 324 patients who received post-
operative adjuvant therapy, 248 (76.5%) received CRT, 23 (7.1%)
received chemotherapy only and for 53 (16.4%) it was uncertain if
they received radiation in addition to documented chemotherapy.
No patient received radiation therapy alone.
Overall mortality and survival
Of 157 censored patients, the median follow-up was 27.7 months
(IQR: 13.9–45.4). Thirty- and 90-day mortality rates were 0.7%
(n = 3) and 1.7% (n = 7). Two additional deaths occurred in the
hospital beyond 90-days. In all, seven (1.7%) of these nine deaths
Table 2 Tumor features
Parameter n (%)
T-Stage
Tx 2 (0.5%)
T1 29 (6.8%)
T2 54 (12.7%)
T3 329 (77.6%)
T4 10 (2.4%)
Nodal invasion (N1) 290 (68.4%)
Metastatic disease (M1) 11 (2.6%)
LNs examined (median/IQR) 14 (10–20)
Positive LNs (median/IQR) 1.5 (0–3)
LNR  0.3 83 (19.6%)
Arising in IPMN 40 (9.4%)
Differentiationa
Well 45 (10.8%)
Moderate 207 (49.5%)
Poor 166 (39.7%)
Lymphovascular invasionb 162 (43.8%)
Perineural invasionc 341 (83.0%)
AJCC Stage, 7th edm
I A 16 (3.8%)
I B 29 (6.8%)
II A 82 (19.3%)
II B 275 (64.9%)
III 10 (2.4%)
IV 11 (2.6%)
a6 missing values.
b54 missing values.
c13 missing values.
IQR, interquartile range; LN, lymph node; LNR, lymph node ratio;
IPMN, intraductal papillary mucinous neoplasm.
Table 3 Post-operative complications
Parameter n (%)
Clavien-Dindo complication score
None 178 (42.0%)
Grade I 52 (12.3%)
Grade II 131 (30.9%)
Grade III a 22 (5.2%)
Grade III b 5 (1.2%)
Grade IV a 26 (6.1%)
Grade IV b 3 (0.7%)
Grade V (death) 7 (1.7%)
ISGPF delayed gastric emptying gradea
None 149 (73.8%)
Grade A 35 (17.3%)
Grade B 7 (3.5%)
Grade C 11 (5.4%)
ISGPS pancreatic fistula grade
None 358 (84.4%)
Grade A 39 (9.2%)
Grade B 24 (5.7%)
Grade C 3 (0.7%)
Wound infection 45 (10.6%)
Respiratory distress 37 (8.7%)
Pneumonia 27 (6.4%)
UTI 27 (6.4%)
Ileus 23 (5.4%)
Bleeding 20 (4.7%)
Sepsis 12 (2.8%)
Wound dehiscence 9 (2.1%)
Biloma 8 (1.9%)
Neurological distress 7 (1.7%)
MI 5 (1.2%)
Acute renal failure 3 (0.7%)
aFrom the University of Pennsylvania Experience Only (n = 202).
ISGPS, The International Study Group on Pancreatic Fistula; UTI, urinary
tract infection; MI, myocardial infarction.
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were attributable to surgical complications (Clavien Grade V).
Surgical deaths were caused by bleeding (n = 1), hepatic failure
(n = 1), infection with resulting organ failure (sepsis/bacteraemia,
n = 3) and unknown causes in the immediate post-operative
period (n = 2). The median survival for all patients was 21.3
months, and 1-, 2-, 3-, 4- and 5-year actuarial survival rates were
76%, 45%, 34%, 28% and 23%, respectively. Of 156 patients with
actual 5-year follow-up, 32 (21%) survived that long. There were
no differences in survival based on surgeon (P = 0.632), institution
(P = 0.288) or operation (P = 0.572, comparison of pancreati-
coduodenectomies vs. distal pancreatectomies).
Surgical audit
The median POSSUM physiological and operative scores were 18
(IQR: 15–23) and 17 (IQR: 17–19), respectively. POSSUM scores
predicted a 61.4% morbidity rate and Portsmouth POSSUM pre-
dicted a 6.9% operative mortality rate. This corresponds to a 0.94
O/E ratio for morbidity and a 0.24 O/E ratio for mortality (using
all surgical-related deaths).
Survival analysis
In studying 107 discreet variables across the full spectrum of
surgical care, factors associated with poor survival were identified
(Table 4). Patients with node negative disease and negative
margins (n = 97) achieved a 37.3-month median survival and had
a 40% 5-year survival.
A Cox’s Proportional Hazard model was constructed to identify
factors independently associated with survival (Table 4). Only the
343 patients (81%) with complete datasets were used in the
model. The most frequently missing data value was lymphovas-
cular invasion (LVI) (n = 54). Kaplan–Meier curves for select
variables are presented in Fig. 1.
The influence of operative transfusions
Patients transfused either during the operation or within the sub-
sequent 24 h demonstrated significantly diminished 5-year sur-
vival compared with those who were not (14% vs. 27%). Further
scrutiny shows that operatively transfused patients had worse pre-
operative physiology and comorbidities, occurred more fre-
quently after downstaging CRT, occurred more often in classical
pancreaticoduodenectomies and had increased operative blood
loss, increased rates of post-operative bleeding, respiratory dis-
tress, and sepsis, worse complication profiles, longer durations of
stay, and significantly increased rates of LVI (not shown). On
multivariate logistic regression, pre-operative physiology and
operative blood loss were independently associated with operative
transfusion (POSSUMPhysiology Score,HR: 1.14,P < 0.001: EBL,
HR: 36.8, P < 0.001), whereas tumour-related factors were not.
Transfusions administered after the first day did not appear to
have any detrimental effect on ultimate survival.
Lymph node analysis
Survival for N1 patients with a single positive node (N1-a; n = 77)
was compared with those with more than one positive node
(N1-b; n = 213). The two populations had similar median and
5-year survivals (N1-a 21.2 m/21%; N1-b 18.6 m/20%, P = 0.335).
While the survival difference between patients with a single iso-
lated node and N0 patients was not statistically significant, the
disparity was more striking (N0 31.4 m/31%, P = 0.065).
Intraductal Papillary Mucinous Neoplasm
While intraductal papillary mucinous neoplasm (IPMN) patients
had improved long-term survival over other patients, the differ-
ence was not statistically significant (5-year survival: 46% vs. 22%,
P = 0.354). IPMN patients had more optimistic AJCC staging,
with Stage I tumours occurring in 32% of patients compared with
8% in non-cystic PDACs (P < 0.001). Stage I tumors accounted for
10 out of 13 IPMN patients with actual 5-year survival. Lower
T-stage (T1/T2) was present in 16 (40.0%) IPMN patients vs. 67
(17.5%) non-cystic patients (P = 0.002). Node negative disease
was present in 19 (47.5%) IPMN patients vs. 115 (29.9%) non-
cystic patients (P = 0.031). Perineural invasion was present in
21/36 (58.3%) IPMN patients with available pathological data vs.
320/375 (85.3%) non-cystic patients (P < 0.001 & P = 0.065). R0
resections were achieved in 34 (85.0%) IPMN patients vs. 242
(63.0%) non-cystic patients (P = 0.005). Differences in tumour
grade and LVI rates for IPMN patients were not statistically
significant.
Discussion
Results from this contemporary (2000s) combined-institution
study demonstrate continued progress in patient outcomes after
resection for pancreatic adenocarcinoma. The 30-day mortality
rate (0.7%) is particularly encouraging, indicating that surgical
safety continues to improve in high-volume centres33 (Table 5).
Two key metrics of post-operative surgical management, pancre-
atic fistulae and major complications, were found to be limited in
both scope and impact on patient survival. Furthermore 76% of
patients survived the first year post-operatively, which compares
favourably with historical standards and suggests significant
improvements in peri- and post-operative management.
Optimism based on these improved immediate-term surgical
outcomes must be tempered by a recognition that advances in
post-operative oncological treatment and long-term survival have
not yet been realized. While the actual 5-year survival rate (21%)
corresponds with the upper limit of previously reported figures, it
is comparable to outcomes achieved by some institutions in the
5-FU era of the 1980s and 1990s (Table 5).While operative results
have improved, these numbers indicate that the underlying
aggressive tumour biology has not been significantly altered by
modern post-operative treatments.
The present study found that the 79.2% of patients received
post-operative adjuvant or palliative therapy (with an additional
5.7% of unknown treatment status), which stands in sharp con-
trast to the national average of 49.0% reported by Bilimoria et al.34
This increased utilization of adjuvant therapy may partially
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Table 4 Survival analysis and cox regression model
Parameter Category Survival Cox model
Mediana 5-years P Hazard P
Gender Male 21.6 23% 0.566
Female 21.2 24%
Age <75 years 22.1 26% 0.138
 75 years 19.4 15%
Pre-operative jaundice No 26.5 20% 0.204
Yes 19.7 24%
Pre-operative weight loss None or <10% 22.3 25% 0.088
10% 18.9 20%
HTN No 22.7 27% 0.105
Yes 20.4 21%
Diabetes No 22.7 25% 0.101
Yes 19.5 21%
ASA 1 or 2 26.4 32% 0.020
3 or 4 19.7 19%
Charlson comorbidity score Continuous <0.001
POSSUM physiological score Continuous 0.001 1.03 0.036
POSSUM operative score Continuous <0.001
SOAR score Continuous 0.054
Resection PPPD 21.3 24% 0.475
Classic PD 18.5 24%
Distal 20.7 13%
Total 32.2 49%
OR time Continuous 0.641
Estimated blood loss 0–999 ml 21.6 25% 0.023
1000 ml 16.6 15%
Vascular resection No 21.2 24% 0.901
Yes 21.3 17%
Operative transfusion No 24.5 27% 0.002 1 0.001
Yes 18.8 14% 1.66
Any hospital transfusion No 24.8 27% 0.007
Yes 19.2 18%
Reoperation No 21.3 24% 0.464
Yes 21.1 20%
Duration of stay <21 days 21.6 25% 0.012
21 days 13.3 0%
Clavien complication scoreb None 21.3 22% 0.43
Grade I 19.7 24%
Grade II 23.8 27%
Grade III a 21.2 31%
Grade III b 27.4 36%
Grade IV a 19.1 12%
Grade IV b 16.4 0%
ISGPS pancreatic fistula None 20.3 22% 0.133
Grade A 27.8 20%
Grade B 32.2 45%
Grade C 6.5 0%
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Table 4 Continued
Parameter Category Survival Cox model
Mediana 5-years P Hazard P
ISGPS delayed gastric None 19.2 21% 0.328
Emptyingc Grade A 19.4 16%
Grade B NR 54%
Grade C 27.9 19%
Post-operative sepsis No 21.5 24% 0.012
Yes 5.8 NA
Post-operative bleeding No 21.5 24% 0.202
Yes 17.7 15%
Margins R0 27.1 29% <0.001 1 <0.001
R1 16.8 14% 1.67
T-Stage T1/T2 45.0 46% <0.001 1 0.003
T3/T4 19.7 18% 1.90
N-Stage N0 31.4 31% 0.001
N1 19.2 20%
LNR < .3 24.8 27% <0.001 1 <0.001
 .3 15.5 9% 1.97
Tumour size (cm) Continuous <0.001 1.10 0.034
Distant metastases No 21.3 25% 0.173
Yes 16.6 0%
Differentiation Well/Moderate 27.8 31% <0.001 1 <0.001
Poor 16.8 12% 1.94
Lymphovascular invasion No 27.8 28% 0.001 1 0.006
Yes 18.8 16% 1.5
Perineural invasion No 31.0 34% 0.014
Yes 20.1 21%
Arising in IPMN No 21.3 22% 0.354
Yes 21.2 46%
Oncological therapy None 9.4 23% 0.002
Adjuvant 22.6 26%
Palliative 16.6 0%
Neoadjuvant 17.8 NA
Unknown 16.3 17%
Oncological therapy Any (adj, pal, neo) 22.2 24% <0.001 1 <0.001
None 9.4 23% 3.31
Adjuvant therapy Chemotherapy Only 15.4 13% <0.001
Chemoradiation 26.4 30%
Unknown 17.3 6%
Statistically significant values shown in bold.
aIn months.
bExcludes grade V complications(deaths).
cFrom The University of Pennsylvania experience only.
ASA, American Society of Anesthesiologists; HTN, hypertension; ISGPS, The International Study Group on Pancreatic Fistula; .IPMN, intraductal
papillary mucinous neoplasm.; LNR, lymph node ratio.
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None 
Transfusion 
None - censored 
Transfusion - censored 
P = 0.002
None          308       219     118       62         40         26 
Transfusion 116       74        29        17          9          6 
(a)
P < 0.001
 Well         45         41        24        19         13         8 
 Moderate 207       152      78        38         23        12 
 Poor        166        95        42        20         11        10 
(c)
Well 
Moderate 
Well - censored 
Moderate - censored 
Poor 
Poor - censored 
P < 0.001(b)
CRT 
Chemo only 
CRT - censored 
Chemo only - censored 
(d) P < 0.001
CRT          248       206      106       59        38         24 
Chemo Only   23         13         4           1          1           0 
N0 
LNR < 0.3 
N0 - censored 
LNR < 0.3 - censored 
LNR ≥ 0.3 
LNR ≥ 0.3 - censored 
N0              134       106      62        38         22        15 
LNR < 0.3   207       140      71        35         24        14 
LNR ≥ 0.3   83          47       14        6           3           3  
Subtotal 
Total 
Subtotal - censored 
Total - censored 
Subtotal   402       277     138       73         46         30 
Total        22         16        9          6           3           2 
P = 0.227(e)
Non-IPMN 
IPMN 
Non-IPMN - censored 
IPMN - censored 
P = 0.354
Non-IPMN 384       267     134        71         45         28 
IPMN        40         26       13          8           4           4 
(f)
Figure 1 (a) Survival by use of peri-operative (operation and 24-h post-operatively) transfusion. Survival was significantly longer in patients
without peri-operative transfusions (P = 0.002). (b) Survival by lymph node ratio (LNR). Survival was different between LNR groupings (P <
0.001). N1 patients with LNR < 0.3 had significantly longer survival than patients with LNR 0.3 (P < 0.001), but survival was not significantly
different between N1 patients with LNR <0.3 and N0 patients (P = 0.068). (c) Survival by tumour differentiation. Survival was significantly
different between grades (P < 0.001). (d) Survival by adjuvant therapy received. Among patients who received post-operative adjuvant
therapy with curative intent, those who received chemoradiation therapy (CRT) had a significantly longer survival than those who received
chemotherapy only (P < 0.001). (e) Survival by extent of resection. Survival was not significantly different by resection type (P = 0.227).
(f) Survival by presence of intraductal papillary mucinous neoplasm (IPMN). Survival was not significantly different by presence of IPMN
(P = 0.354)
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explain the discrepancy between survival numbers from national
sources and high-volume centres. Both institutions in this study
have integrated multidisciplinary systems in place designed to
successfully deliver patients from the surgeon to the oncologist,
and this may represent one of the greatest assets of high-volume
specialty programmes.
POSSUM has yet to be assessed as an independent predictor of
survival after resection for PDAC. The current finding that poor
pre-operative physiology, as measured by POSSUM, dampens sur-
vival highlights the versatility and utility of the POSSUM score
and also emphasizes the importance of pre-operative physiology
to achieving long-term survival. For patients demonstrating poor
pre-operative physiology, the decision to operate should be
approached with increased caution and efforts to bolster physical
status should be considered pre-operatively. For its intended use
in surgical audit, POSSUM has previously been shown to accu-
rately estimate post-operative morbidity,35 but this study has now
shown POSSUM to be inadequate at estimating post-operative
mortality. The discrepancy in observed and expected mortality
suggests that the POSSUM mortality equation needs to be recali-
brated for pancreatic surgery.
The association of blood loss and intra-operative transfusions
with long-term survival for resected PDAC has been observed
previously.6,36,37 The immunosuppressive effect of an allogeneic
blood transfusion was originally demonstrated in the 1970s when
reports showed reduced rates of kidney-graft rejection among
heavily transfused patients.38–40 More recent studies in potentially
curative resection for colorectal cancer and breast cancer have
associated transfusion with increased rates of recurrence, peri-
operative mortality, length of stay and complications.41–43 The
current study corroborates these findings, although increased
peri-operative mortality was not observed in the transfused
group. A more recent study has suggested a biochemical response
by which blood transfusion and surgical stress may synergisti-
Table 5 Selected reports of comprehensive experiences with resected pancreatic ductal adenocarcinoma (PDAC), 1970 present
Author Years n Mortality Survivala Scope
30d 90d Surgical Median
(months)
1-year 3-year 5-year 5-year,
actual
Yeo8 1970–1994 201 5.0b NA NA 15.5 57 26 21 15 SI – Hopkins
Mayo56 1970–2008 1822 NA NA NA 18 68.3 38.9 18 NA SI – Hopkins
Trede57 1972–1989 133 2.2b NA NA NA NA NA 24c NA SI – Mannheim
Schnelldorfer58 1981–2001 357 1.4b NA NA 17 NA NA 18 17.4 SI – Mayo Clinic
Conlon7 1983–1989 118 3.4 NA NA 14.3 NA NA 10.2 10.2 SI – MSKCC
Winter5 1983–1989 123 4.9 7.3 NA 23.2f 58 NA 17f NA SI – MSKCC
Geer59 1983–1990 146 3.4 NA NA NA NA NA 24 19.2 SI – MSKCC
Ferrone60 1983–2001 618 1.1 NA NA NA NA NA NA 11.8 SI – MSKCC
Sohn6 1984–1999 616 2.3b NA 2.3 17 63 25 17 17 SI – Hopkins
Sener61 1985–1995 9044 NA NA NA NA NA NA 23.4 NA NCDB
Wade62 1987–1991 252 8.3 NA NA 15d NA NA 9 NA Dept. Vet. Affairs
Cleary63 1988–1996 123 NA NA 4.8 13.6 NA NA 14.6 14.6 SI – Toronto
Baxter64 1988–2002 2919 NA NA NA 17e NA NA NA NA SEER
Winter5 1990–1999 399 1.5 3.0 NA 25.6f 68 NA 20f NA SI – MSKCC
Bilimoria1 1992–1998 21512 NA NA NA 12.6 52 19.1 12.6 12.6 NCDB
van Geenen65 1992–1998 108 NA NA NA 16 NA NA NA NA SI – Amsterdam
Konstantinidis66 1993–2008 517 0.8 NA NA 19.7 NA NA 17.3 NA SI – Mass General
Evans67h 1998–2001 64 1.6g NA NA 34 NA NA 36 NA SI – MD Anderson
Winter5 2000–2009 625 1.3 3.9 NA 24.5f 68 NA 8f NA SI – MSKCC
Present Study 2001–2011 424 0.7 1.7 1.7 21.3 76 34 23 21 DI – Penn & BIDMC
aActuarial.
bIn-hospital.
cExcludes in-hospital mortalities.
dMean.
eCalculated from diagnosis; only includes patients that survived 3 months from diagnosis.
fOnly includes patients that survived 1-year.
gPeri-operative death.
hReflects only patients who completed neoadjuvant therapy and received surgical resection.
DI, dual institution; SI, single institution. NA, not applicable.
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cally affect prognosis.44 In the current analysis, operative trans-
fusions were adversely associated with survival, whereas
subsequent post-operative (POD1 +) transfusions were not,
supporting the idea that surgical stress and transfusions interact
synergistically.
While blood loss and operative transfusions are the result of
many factors, including the extent of tumour invasion, vascular
involvement and surgeon skill, this study shows improved
outcomes when transfusions are not applied. To this end, a
blood transfusion has recently been proposed as a quality metric
for pancreatic resection.45 Surgeons should strive to minimize
blood loss through meticulous dissection, particularly in light
of the irrelevance of operating time seen in this study, and the
operative safety at relatively low Hgb counts demonstrated
previously.46
Recent studies have suggested that the LNR is a more refined
indicator of prognosis than node status.47,48 However, variability
exists within the literature as to appropriate cut-off values.47,48 In
this study, the LNR cut-off value of 0.3 was chosen for modelling
after assessing the prognostic ability of the LNR as a continuous
variable, as well as at all decile levels. The value of 0.3 provided
the most significant discrimination in overall survival in the
overall population and in the cohort of N1 patients alone. Fur-
thermore, studies have pointed to the importance of both total
lymph nodes examined and total positive nodes as significant
prognostic factors.49 Of the various measures of nodal disease in
this series (N-stage, LN ratio and total positive nodes), the LN
ratio was the most significant predictor of survival, although all
other values were highly predictive (P < 0.001). Total nodes
examined was not significant (P = 0.772). This study confirms
prior reports that the LN ratio provides refined predictive capac-
ity and suggests a preferred cutoff value of 0.3 for reporting of
LN ratio prognostics.
Patients with invasive PDAC arising in IPMN are felt to have
improved long term survival compared with non-IPMN associ-
ated PDAC, with 5-year survival reported in the range of
42–60%.50,51 However, it has been suggested that when staging
differences are taken into account, the prognosis is equivalent
between tumour types.50,52 While the results of this study show an
actuarial 5-year survival for IPMN in line with previous reports
(46%), the overall survival was not found to be significantly dif-
ferent from non-cystic patients – reflective of the unusual survival
curve generated from the IPMN patients, and the small number of
patients present for analysis after 2-years. Additionally, IPMN
patients had earlier stage tumours than non-cystic PDAC patients,
along with lower rates of perineural invasion and R1 resections.
These results appear to agree with earlier findings that while long-
term survival is enhanced for PDAC arising in IPMN, this is likely
attributable to earlier stage presentations and not actually a more
indolent tumour behaviour.
Historically, the value of total pancreatectomies for adenocar-
cinoma patients has been questioned because of concerns about
operative mortality, metabolic lability, and long-term survival. A
recent study on causes of mortality after a pancreatic resection
showed a total pancreatectomy, particularly in the setting of
PDAC, to be highly lethal.9 On the contrary, this study has dem-
onstrated optimistic outcomes for total pancreatectomies, with no
30-day deaths among total resections, and a lower incidence of
complications than other resections (45.5% vs. 58.7%, P = 0.324).
Furthermore, survival was better for total pancreatectomies than
any other resection type (32.2 m median, 49% 5 year). This is
reflective of the increased incidence of IPMN (41%) and stage I
tumours (18%) in total pancreatectomies. These results corrobo-
rate more recent studies showing the value of total pancreatecto-
mies when required oncologically.53,54
A national study by Bilimoria et al. reported the underutiliza-
tion of surgery for early stage tumours, particularly among the
elderly.16 This represents a potential area for improvement of care
dependent on improved processes and systems. The short-term
safety and long-term benefit of resection in the elderly is ques-
tioned today,55 as it has been for decades.While this study found a
higher rate of overall complications among 101 elderly (75
years) patients (74.3% vs. 52.9%, P < 0.001), they accounted for
none of the 30-day deaths. Furthermore, the overall survival for
the elderly was not statistically different from the younger cohort
(P = 0.138). These results agree with earlier findings associating
old age with morbidity but do not support the association with
increasedmortality rates, whichmay indicate an improving ability
to manage post-operative complications in the elderly population.
These results demonstrate that elderly patients are able to with-
stand the stress of surgery and obtain the survival benefits
achieved by younger patients.
Conclusion
Peri-operative outcomes for a resected pancreatic adenocarci-
noma continue to improve, highlighting the significant achieve-
ments in surgical care over the past three decades. This series
demonstrates that extended survival is affected by tumour
biology, pre-operative physiology and some operative factors
under the surgeon’s control, specifically, negative margin resec-
tion and low blood loss/transfusion-less surgery. Operative mor-
tality, now minimized, along with improved management of
complications, currently allows for more consistent delivery of
patients to the oncologist for application of adjuvant therapy. As
first suggested by Peter Allen in 2007, such improvements have
enhanced early outcomes, putting ‘a hump’ in the pancreatic
cancer survival curve. However, long-term results remain frustrat-
ingly poor. As patients and physicians wait for effective chemo-
therapeutics to influence ultimate prognosis, surgeons continue to
improve survival through constant refinement of their approaches
to this disease.
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